Table 2B:
The distribution of pathology scores based on Banff criteria for antibody-mediated rejection for the first (if more than one per patient available) kidney allograft biopsies obtained prior to urinary microbiome sample collection described in Table 2A.
| Case (N=19) | Control (N=11) | |||||||
|---|---|---|---|---|---|---|---|---|
| Biopsy Score | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 |
| i (interstitial inflammation) | 83% | 6% | 6% | 6% | 91% | 9% | 0% | 0% |
| t (tubulitis) | 72% | 11% | 6% | 11% | 82% | 9% | 9% | 0% |
| ci (interstitial fibrosis) | 50% | 33% | 17% | 0% | 73% | 18% | 9% | 0% |
| ct (tubular atrophy) | 44% | 39% | 17% | 0% | 64% | 36% | 0% | 0% |
| cv (vascular fibrosis) | 67% | 17% | 17% | 0% | 82% | 18% | 0% | 0% |
| cg (glomerulopathy) | 94% | 6% | 0% | 0% | 100% | 0% | 0% | 0% |
| ah (arteriolar hyaline thickening) | 83% | 17% | 0% | 0% | 73% | 27% | 0% | 0% |
| v (intimal artertitis) | 100% | 0% | 0% | 0% | 91% | 9% | 0% | 0% |
| g (glomerulitis) | 100% | 0% | 0% | 0% | 100% | 0% | 0% | 0% |
| Other Laboratory Data | ||||||||
| Positive | Negative | Not Done | Positive | Negative | Not Done | |||
| C4d staining | 0% | 42% | 58% | 0% | 64% | 36% | ||